Liraglutide
- TRADE NAME: Victoza (Novo Nordisk)
- INDICATIONS: To improve glycemic control in adults with Type II diabetes mellitus
- CLASS: Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: 13 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Atorvastatin, Digoxin, Griseofulvin, Lisinopril, Warfarin
PREGNANCY CATEGORY: C
Risk of thyroid C-cell tumors.
Contraindicated in patients with a personal or family history of MTC or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2).
Please login to see the rest of this drug profile
SKIN
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
NEUROMUSCULAR/SKELETAL
GASTROINTESTINAL/HEPATIC
RESPIRATORY
ENDOCRINE/METABOLIC
GENITOURINARY
RENAL
LOCAL
OTHER
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life Threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric